全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma)):治療薬開発パイプライン動向2018

◆英語タイトル:Systemic Sclerosis (Scleroderma)-Pipeline Insights, 2018
◆商品コード:DIPR2016638
◆発行会社(調査会社):DelveInsight
◆発行日:2018年09月
◆ページ数:約60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥137,500見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※本調査レポートでは、世界における全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma))の治療薬開発パイプライン動向について調査・分析し、企業別開発中の治療薬、各臨床試験段階における製品リスト及び比較分析、薬剤候補のプロファイル、治療薬の評価、開発中止又は開発休止中の薬剤リスト等をお届けしています。また、全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma))治療薬開発に取り組んでいる企業情報も提供しています。

・全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma))の概要

・全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma))の治療薬パイプライン概要

・企業別開発中の全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma))治療薬

・後期治験段階の薬剤(Filed & Phase III):比較分析

・中期治験段階の薬剤(Phase II):比較分析

・初期治験段階の薬剤(Phase I & IND Filed):比較分析

・前臨床段階の薬剤:比較分析

・薬剤候補のプロファイル

・全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma))治療薬の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価

・開発が中止された薬剤リスト

・開発休止中の薬剤リスト

・全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma))治療薬開発に取り組んでいる企業リスト

・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “ Systemic Sclerosis (Scleroderma)-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Systemic Sclerosis (Scleroderma). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Systemic Sclerosis (Scleroderma). DelveInsight’s Report also assesses the Systemic Sclerosis (Scleroderma) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitivepipeline landscape of Systemic Sclerosis (Scleroderma)
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Systemic Sclerosis (Scleroderma) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Systemic Sclerosis (Scleroderma) and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Systemic Sclerosis (Scleroderma) Overview
• Systemic Sclerosis (Scleroderma) Pipeline Therapeutics
• Systemic Sclerosis (Scleroderma) Therapeutics under Development by Companies
• Systemic Sclerosis (Scleroderma) Filed and Phase III Products
• Comparative Analysis
• Systemic Sclerosis (Scleroderma) Phase II Products
• Comparative Analysis
• Systemic Sclerosis (Scleroderma) Phase I and IND Filed Products
• Comparative Analysis
• Systemic Sclerosis (Scleroderma) Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Systemic Sclerosis (Scleroderma) – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Systemic Sclerosis (Scleroderma) – Discontinued Products
• Systemic Sclerosis (Scleroderma) – Dormant Products
• Companies Involved in Therapeutics Development for Systemic Sclerosis (Scleroderma)
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Systemic Sclerosis (Scleroderma), 2018
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2018
• Comparative Analysis Phase II Products, 2018
• Comparative Analysis Phase I and IND Filed Products, 2018
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2018
• Drug Candidates Profiles
• Systemic Sclerosis (Scleroderma) Assessment by Monotherapy Products
• Systemic Sclerosis (Scleroderma) Assessment by Combination Products
• Systemic Sclerosis (Scleroderma) Assessment by Route of Administration
• Systemic Sclerosis (Scleroderma) Assessment by Stage and Route of Administration
• Systemic Sclerosis (Scleroderma) Assessment by Molecule Type
• Systemic Sclerosis (Scleroderma) Assessment by Stage and Molecule Type
• Systemic Sclerosis (Scleroderma) Therapeutics – Discontinued Products
• Systemic Sclerosis (Scleroderma) Therapeutics – Dormant Products
• Products under Development by Companies, 2018


List of Figures
• Number of Products under Development for Systemic Sclerosis (Scleroderma), 2018
• Filed and Phase III Products, 2018
• Phase II Products, 2018
• Phase I and IND Filed Products, 2018
• Discovery and Pre-Clinical Stage Products, 2018
• Systemic Sclerosis (Scleroderma) Assessment by Monotherapy Products
• Systemic Sclerosis (Scleroderma) Assessment by Combination Products
• Systemic Sclerosis (Scleroderma) Assessment by Route of Administration
• Systemic Sclerosis (Scleroderma) Assessment by Stage and Route of Administration
• Systemic Sclerosis (Scleroderma) Assessment by Molecule Type
• Systemic Sclerosis (Scleroderma) Assessment by Stage and Molecule Type


【レポートのキーワード】

全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma))、治療薬、医薬品、薬剤、製薬企業、研究開発、治験、パイプライン

★調査レポート[全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma)):治療薬開発パイプライン動向2018] (コード:DIPR2016638)販売に関する免責事項を必ずご確認ください。
★調査レポート[全身性硬化症(皮膚硬化症)(Systemic Sclerosis (Scleroderma)):治療薬開発パイプライン動向2018]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆